BrightInsight, a provider of the global platform for biopharma and medtech-regulated digital health solutions, has announced the addition of ixlayer in its BrightInsight Ecosystem.
Launched in September 2022, the BrightInsight Ecosystem brings together leaders from across the healthcare industry, including bioMérieux, Google Cloud, Lyniate and Xealth, collectively focused on advancing digital innovation to improve patient care globally.
Drug companion apps built leveraging BrightInsight’s Disease Management Solution on the compliant BrightInsight Platform can incorporate ixlayer’s convenient diagnostic testing. The integration between the BrightInsight and ixlayer platforms will enable biopharma companies to deliver a seamless digital experience for their patients, reduce the burden of in-person diagnostic testing, accelerate therapy matching, and provide a feedback loop to patients on the effectiveness of their therapy, ultimately with the goal of improving persistence.
The companies see a huge opportunity to enhance the patient journey – from diagnosis to therapy matching, disease management, and monitoring of adverse side effects – by making it more convenient and streamlined through digital.
For conditions such as high cholesterol, chronic kidney disease, diabetes and autoimmune diseases, such as psoriasis and rheumatoid arthritis, diagnostic testing is a prerequisite for patients to qualify for certain therapies. In-person diagnostic testing is inconvenient and creates useless friction for patients in obtaining prior authorization.
Post-diagnosis, while on therapy, patients can also perceive a lack of drug effectiveness because they do not have a regular feedback loop, which leads to poor persistence. Diagnostic testing can also be required to monitor for adverse side effects of therapies.
Integrating drug companion apps with diagnostic testing offers significant benefits across key stakeholders:
Patients experience a more streamlined journey to start on effective treatments and can access data around the effectiveness of their therapy all through their app.
Clinicians will have increased confidence in getting the right patients on the right treatment and can alleviate the practice burden from implementing diagnostic testing to qualify patients for certain medications.
Biopharma companies can deliver a seamless experience to facilitate patient adoption and continued adherence to support better health outcomes by removing barriers to testing.
"Our partnership with ixlayer is a perfect example of how integrating data across two compelling platforms can provide more value to patients, clinicians and our life sciences customers,” said Kal Patel, M.D., CEO and Co-Founder of BrightInsight in a news release.
Click here to read the original news story.